doxycycline delayed-release / Generic mfg. - LARVOL DELTA

Characterization of Doxycycline Pharmacokinetics and Adherence (clinicaltrials.gov) - P1 | N=16 | Enrolling by invitation | Sponsor: HIV Prevention Trials Network | Not yet recruiting ➔ Enrolling by invitation

Enrollment open • Infectious Disease

Characterization of Doxycycline Pharmacokinetics and Adherence (clinicaltrials.gov) - P1 | N=16 | Not yet recruiting | Sponsor: HIV Prevention Trials Network

New P1 trial • Infectious Disease

PNOC039: Isotretinoin vs. Doxycycline for Acneiform Rash in Patients Receiving Drugs That Target the MAPK Pathway (clinicaltrials.gov) - P2 | N=50 | Not yet recruiting | Sponsor: University of California, San Francisco

New P2 trial • Dermatology

Doxycycline Prophylaxis for Prevention of Sexually Transmitted Infections (clinicaltrials.gov) - P4 | N=760 | Recruiting | Sponsor: Westat | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease

Doxycycline Prophylaxis for Prevention of Sexually Transmitted Infections (clinicaltrials.gov) - P4 | N=760 | Not yet recruiting | Sponsor: Westat | Initiation date: May 2025 ➔ Nov 2025 | Trial primary completion date: Jun 2027 ➔ May 2028

Trial initiation date • Trial primary completion date • Infectious Disease

Pay-it-forward and social network distribution to increase doxycycline post-exposure prophylaxis uptake among men who have sex with men and transgender women in China: a three-arm randomized controlled trial (ChiCTR) - P=N/A | N=399 | Recruiting | Sponsor: Dermatology Hospital of Southern Medical University; Dermatology Hospital of Southern Medical University | Not yet recruiting ➔ Recruiting | Phase classification: P1 ➔ PN/A | N=75 ➔ 399

Enrollment change • Enrollment open • Phase classification • Infectious Disease

Doxycycline to prevent bacterial sexually transmitted infections in the USA: final results from the DoxyPEP multicentre, open-label, randomised controlled trial and open-label extension. (PubMed, Lancet Infect Dis) - P4 | "Doxy-PEP was effective in reducing bacterial STIs in this population of men who have sex with men and transgender women, including during an open-label extension when doxy-PEP efficacy was known. Doxy-PEP was well tolerated, highly acceptable, and with no new safety signals."

Journal • Infectious Disease

Doxycycline Prophylaxis for Prevention of Sexually Transmitted Infections (clinicaltrials.gov) - P4 | N=760 | Suspended | Sponsor: Westat | Not yet recruiting ➔ Suspended

Trial suspension • Infectious Disease

Doxycycline Prophylaxis for Prevention of Sexually Transmitted Infections (clinicaltrials.gov) - P4 | N=760 | Not yet recruiting | Sponsor: Westat | Phase classification: P3 ➔ P4

Phase classification • Infectious Disease

foXXxy doxy: Doxycycline Prophylaxis for Prevention of Sexually Transmitted Infections (clinicaltrials.gov) - P3 | N=760 | Not yet recruiting | Sponsor: Westat

New P3 trial • Infectious Disease

Pembrolizumab with Intratumoral Injection of Clostridium Novyi-NT (clinicaltrials.gov) - P1 | N=18 | Active, not recruiting | Sponsor: M.D. Anderson Cancer Center | Trial completion date: Oct 2024 ➔ Oct 2026 | Trial primary completion date: Oct 2024 ➔ Oct 2026

Combination therapy • Trial completion date • Trial primary completion date • Brain Cancer • Breast Cancer • CNS Tumor • Endocrine Cancer • Eye Cancer • Gastrointestinal Cancer • Gynecologic Cancers • Oncology • Oral Cancer • Solid Tumor • Thyroid Gland Carcinoma • PD-L1

Trial of Combination Therapy to Treat COVID-19 Infection (clinicaltrials.gov) - P1 | N=31 | Completed | Sponsor: ProgenaBiome | Active, not recruiting ➔ Completed

Trial completion • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Pembrolizumab With Intratumoral Injection of Clostridium Novyi-NT (clinicaltrials.gov) - P1 | N=18 | Active, not recruiting | Sponsor: M.D. Anderson Cancer Center | Recruiting ➔ Active, not recruiting

Combination therapy • Enrollment closed • Brain Cancer • Breast Cancer • CNS Tumor • Endocrine Cancer • Eye Cancer • Gastrointestinal Cancer • Gynecologic Cancers • Oncology • Oral Cancer • Solid Tumor • Thyroid Gland Carcinoma • PD-L1

Drugs for acne. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Acne Vulgaris

Efficacy of Doxycycline on Metakaryote Cell Death in Patients With Resectable Pancreatic Cancer (clinicaltrials.gov) - P2 | N=12 | Completed | Sponsor: Medical College of Wisconsin | Active, not recruiting ➔ Completed | Trial completion date: Jul 2024 ➔ May 2022

Trial completion • Trial completion date • Gastrointestinal Cancer • Hepatology • Oncology • Pancreatic Adenocarcinoma • Pancreatic Cancer • Solid Tumor

Pembrolizumab With Intratumoral Injection of Clostridium Novyi-NT (clinicaltrials.gov) - P1 | N=18 | Recruiting | Sponsor: M.D. Anderson Cancer Center | Trial completion date: Oct 2021 ➔ Oct 2024 | Trial primary completion date: Oct 2021 ➔ Oct 2024

Trial completion date • Trial primary completion date • Brain Cancer • Breast Cancer • CNS Tumor • Endocrine Cancer • Eye Cancer • Gastrointestinal Cancer • Gynecologic Cancers • Oncology • Oral Cancer • Solid Tumor • Thyroid Gland Carcinoma • Urothelial Cancer • PD-L1

Lefamulin for M. Genitalium Treatment Failures (clinicaltrials.gov) - P1/2 | N=40 | Recruiting | Sponsor: University of Washington | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease

Lefamulin for M. Genitalium Treatment Failures (clinicaltrials.gov) - P1/2; N=40; Not yet recruiting; Sponsor: University of Washington

New P1/2 trial • Infectious Disease

Trial of Combination Therapy to Treat COVID-19 Infection (clinicaltrials.gov) - P1; N=31; Active, not recruiting; Sponsor: ProgenaBiome; Phase classification: P2 ➔ P1

Clinical • Combination therapy • Phase classification • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • CRP

Trial of Combination Therapy to Treat COVID-19 Infection (clinicaltrials.gov) - P2; N=31; Active, not recruiting; Sponsor: ProgenaBiome; Recruiting ➔ Active, not recruiting

Clinical • Combination therapy • Enrollment closed • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • CRP

DUAL: A Study to Compare Efficacy and Safety of Trifarotene Cream When Used With an Oral Antibiotic for the Treatment of Severe Acne Vulgaris (AV) (clinicaltrials.gov) - P4; N=202; Completed; Sponsor: Galderma R&D; Active, not recruiting ➔ Completed

Clinical • Trial completion • Acne Vulgaris • Dermatology

DUAL: A Study to Compare Efficacy and Safety of Trifarotene Cream When Used With an Oral Antibiotic for the Treatment of Severe Acne Vulgaris (AV) (clinicaltrials.gov) - P4; N=198; Active, not recruiting; Sponsor: Galderma R&D; Enrolling by invitation ➔ Active, not recruiting; Trial completion date: Apr 2021 ➔ Aug 2021; Trial primary completion date: Apr 2021 ➔ Aug 2021

Clinical • Enrollment closed • Trial completion date • Trial primary completion date • Acne Vulgaris • Dermatology

Efficacy of Doxycycline on Metakaryote Cell Death in Patients With Resectable Pancreatic Cancer (clinicaltrials.gov) - P2; N=12; Active, not recruiting; Sponsor: Medical College of Wisconsin; Trial completion date: Jul 2023 ➔ Jul 2024; Trial primary completion date: Apr 2021 ➔ Apr 2022

Clinical • Trial completion date • Trial primary completion date • Gastrointestinal Cancer • Hepatology • Oncology • Pancreatic Adenocarcinoma • Pancreatic Cancer • Solid Tumor

Trial of Combination Therapy to Treat COVID-19 Infection (clinicaltrials.gov) - P2; N=30; Recruiting; Sponsor: ProgenaBiome; Trial completion date: Jul 2021 ➔ Jul 2022; Trial primary completion date: May 2021 ➔ May 2022

Clinical • Combination therapy • Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • CRP

Pembrolizumab With Intratumoral Injection of Clostridium Novyi-NT (clinicaltrials.gov) - P1; N=18; Recruiting; Sponsor: M.D. Anderson Cancer Center; Trial primary completion date: Oct 2020 ➔ Oct 2021

Clinical • Combination therapy • Trial primary completion date • Brain Cancer • Breast Cancer • CNS Tumor • Endocrine Cancer • Eye Cancer • Gastrointestinal Cancer • Gynecologic Cancers • Oncology • Oral Cancer • Solid Tumor • Thyroid Gland Carcinoma • Urothelial Cancer • PD-L1